Evolocumab In Advanced Chronic Kidney Disease Trial

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2021

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
110 individuals with stage 4-5 Chronic Kidney Disease (CKD) will be randomized to 1-year of blinded Evolocumab or placebo. Subjects will undergo evaluation of circulating lipids at baseline and end of study. A substudy including 50 subjects will assess myocardial rest and stress positron emission tomography (PET) at baseline and at 1-year.
Epistemonikos ID: a2b62fffb2b03e0d0abf7fa80662bce13f6b9f56
First added on: May 07, 2024